Why Champions Oncology, Inc.’s (CSBR) Stock Is Down 6.44%
As of Tuesday, July 28, Champions Oncology, Inc.’s CSBR share price has dipped by 6.44%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Stock Evaluator: Champions Oncology, Inc. (CSBR)
Champions Oncology, Inc. CSBR
$5.19
-0.11
-2.08%
August 6, 2026 4:00:00 PM
EST
Volume: 15,818
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Commentary & Analysis
Why Champions Oncology, Inc.’s (CSBR) Stock Is Down 6.85%
As of Thursday, July 23, Champions Oncology, Inc.’s CSBR share price has dipped by 6.85%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Champions Oncology, Inc.’s (CSBR) Stock Is Up 6.02%
As of Friday, July 10, Champions Oncology, Inc.’s CSBR share price has surged by 6.02%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Champions Oncology, Inc.’s (CSBR) Stock Is Down 5.91%
As of Tuesday, June 30, Champions Oncology, Inc.’s CSBR share price has dipped by 5.91%, which has investors questioning if this is right time to buy.Michael Rose
Why Champions Oncology, Inc.’s (CSBR) Stock Is Down 8.30%
As of Monday, June 29, Champions Oncology, Inc.’s CSBR share price has dipped by 8.30%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CSBR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $73.6 | $1,888.3 | 19% |
|
| Shares Out (Mil) | 13.9 | 93.8 | 26% |
|
| Institutional Ownership | 60.8% | 90.0% | 39% |
|
| Float (Mil) | 6.1 | 69.9 | 14% |
|
| Beta | 0.39 | 1.17 | 22% |
|
| Avg Daily Volume (000s) | 12 | 864 | 18% |
|
| Price Change (52-week) |
(14.0%) | 82.4% | 33% |
|
| Growth | CSBR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.7% | 7.8% | 49% |
|
| Net Income (5yr) | (38.0%) | (13.7%) | 10% |
|
| EPS (5yr) | (44.3%) | 0.7% | 4 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (5.2%) | (15.0%) | 61% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CSBR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $59 | $785 | 22% |
|
| Net Income (TTM) (Mil) | ($1) | ($14) | 38% |
|
| EPS (TTM) | ($0.085) | ($0.300) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | $53 | 25% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | ($2) | 34% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $154 | 26% |
|
| Enterprise Value (Q1) (Mil) | $76 | $2,444 | 20% |
|
| Valuation | CSBR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 18.93 | 2.95 | 95% |
|
| P/E | na | 37.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.5 | na |
|
| Ratios | CSBR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 48.0% | 47.1% | 60% |
|
| Net Margin | (2.0%) | (2.9%) | 29% |
|
| ROA | (4.0%) | (2.4%) | 32% |
|
| ROE | (30.5%) | (3.0%) | 20% |
|
| Liabilities to Assets | 84.9% | 43.0% | 79% |
|
| F-Score | 3 | 5 | 19% |
|
Champions Oncology, Inc. did not pass any screens on 8/5/2026.
